Table 4. Association between clinical factors and the OS.
| OS (months) | Univariate analysis, Pa | Multivariate analysis, Pb | |
|---|---|---|---|
| Gender | 0.667 | ||
| Male | 17.2 | ||
| Female | 15.0 | ||
| Smoking status | 0.481 | ||
| Smoker(current/former) | 17.2 | ||
| Non-smoker(never) | 14.0 | ||
| EGFR mutation type | 0.905 | ||
| 19-DEL | 14.0 | ||
| L858R | 24.0 | ||
| ECOG PS | 0.067 | ||
| < 2 | 17.2 | ||
| ≥ 2 | 6.2 | ||
| Prior chemotherapy | 0.363 | ||
| 0 | 12.6 | ||
| ≥ 1 | 19.3 | ||
| EGFR-TKI treatment | 0.047 | 0.025 (HR: 0.391, 95%CI: 0.172-0.887) | |
| Erlotinib | 24.0 | ||
| Gefitinib | 11.6 |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; OS, median overall survival; aLog-rank test. bCox regression test.